1. Kazda S, Garthoff B, Meyer H, et al. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1.4-dihydro-2.6 dimethyl-4-(2-nitrophenyl)-3.5-pyridinecarboxylate (nisoldipine, BAY K 5552).Drug Res 1980;30:2144?2162.
2. Warltier DC, Meils CM, Gross GJ, Brooks HL. Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem, and nisoldipine (BAY K 5552), a new dihydropyridine calcium antagonist.J Pharmacol Exp Ther 1981;218:296?301.
3. Maxwell GM, Crompton S, Renics V. Effect of nisoldipine upon the general and coronary hemodynamics of the anaesthetized dog.J Cardiovasc Pharmacol 1982;4:393?399.
4. Warltier D, Zyvoloski M, Gross GJ, Brooks HL. Comparative actions of dihydropyridine slow channel blocking agents in conscious dogs: Systemic and coronary hemodynamics with and without combined beta-adrenergic blockade.J Pharmacol Exp Ther 1984;230:367?375.
5. Jost S, Rafflenbeul W, Mogwitz U, et al. Coronary vasodilation with dihydropyridines?a pharmacokinetic study.Eur Heart J 1989;10(Suppl F):147?152.